Table 1.
Number (and percentage, %) of subjects per biomarker measure at baseline and follow-up, and amount of follow-up days.
| HC (N = 13) |
MCI (N = 49) |
AD dementia (N = 16) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Biomarker | BL | FU | days ± SD | BL | FU | days ± SD | BL | FU | days ± SD |
| Cognitiona | |||||||||
| year 1 | 13 (100) | 12 (92) | 417 ± 33 | 49 (100) | 37 (76) | 413 ± 114 | 16 (100) | 13 (81) | 407 ± 80 |
| year 2 | 10 (77) | 792 ± 40 | 17 (35) | 726 ± 78* | 6 (38) | 737 ± 40 | |||
| AV45-PET | 13 (100) | – | – | 49 (100) | 19 (39) | 373 ± 13 | 16 (100) | 4 (25) | 407 ± 52 |
| FDG-PET | 13 (100) | – | – | 48 (98) | – | – | 16 (100) | – | – |
| CSF | 7 (54) | – | – | 45 (92) | – | – | 15 (94) | – | – |
| MRI | 13 (100) | – | – | 47 (96) | – | – | 16 (100) | – | – |
Abbreviations: AD Alzheimer's disease, BL baseline, CSF cerebrospinal fluid, FU follow-up, HC cognitively healthy control, MCI mild cognitive impairment, MRI magnetic resonance imaging, PET positron emission tomography, SD standard deviation.
*p < 0.05 vs control subjects via Kruskal-Wallis corrected for multiple comparisons via Bonferroni.
a
Cognition, i.e. at least MMSE measurement.